Drug profile · INN
upadacitinib hydrate
RINVOQ PARTIAL CHANGE APPROVAL
upadacitinib hydrate (RINVOQ PARTIAL CHANGE APPROVAL) is a tyrosine-protein kinase jak1 inhibitor.
PMDA: approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — upadacitinib hydrate
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.78
Quick answer
upadacitinib hydrate (RINVOQ PARTIAL CHANGE APPROVAL) is a tyrosine-protein kinase jak1 inhibitor.
Key facts
INN upadacitinib hydrate
Brand RINVOQ PARTIAL CHANGE APPROVAL
Mechanism Tyrosine-protein kinase JAK1 inhibitor
Target Tyrosine-protein kinase JAK1
Mechanism of action
Tyrosine-protein kinase JAK1 inhibitor
Primary target: Tyrosine-protein kinase JAK1
Approval history
| Authority | Status | Date |
|---|---|---|
| PMDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is upadacitinib hydrate?
upadacitinib hydrate (RINVOQ PARTIAL CHANGE APPROVAL) is a tyrosine-protein kinase jak1 inhibitor.
What is the brand name for upadacitinib hydrate?
RINVOQ PARTIAL CHANGE APPROVAL is a marketed brand name for upadacitinib hydrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.